Welcome to Simcyp

Malcolm Rowland, PhD, DSc, DSc(Hons, Poitiers), DPh(Hons, Uppsala), MSc, FRPharmS, FIMA  

Chairman of SAB

Professor Emeritus and former Dean (1998-2001) of the School of Pharmacy and Pharmaceutical Sciences at the University of Manchester, where he was also director (1996-2000) of the Centre for Applied Pharmacokinetic Research.

He is Vice President of FIP (International Pharmaceutical Federation) and a member of the Board of the National Centre for the Replacement, Reduction and Refinement in Animal Research. He was President of EUFEPS (European Federation of Pharmaceutical Sciences) (1996-2000) and founder and former board member of Medeval, a clinical research organisation (1983-2003). He received his degree in pharmacy and his PhD from the University of London, and served on the faculty of the School of Pharmacy, University of California, San Francisco (1967-75).

He has been awarded honorary doctorate degrees from the Universities of Poitiers (France) and Uppsala (Sweden), and is an honorary member of the Royal College of Physicians (London). He has received the 2007 ACCP (American College of Clinical Pharmacology) Distinguished Investigator Award, the Millennial Pharmaceutical Scientist Award (FIP BPS, 2000) and the 1994 AAPS (American Association of Pharmaceutical Scientists) Research Achievement Award in Pharmacokinetics, Pharmacodynamics and Drug Metabolism. He is a fellow of the Academy of Medical Sciences, ACCP(Hon), the Royal Pharmaceutical Society of Great Britain, AAPS, and the Institute of Mathematics. In 2002 he was rated among the top 200 most cited pharmacologists worldwide by the Institute of Scientific Information.

His main research interest is physiologically based pharmacokinetics and its application to drug discovery and development. He is author of over 300 scientific articles and chapters and joint author (with Dr Thomas Tozer) of the textbooks - Clinical Pharmacokinetics: Concepts and Applications and Introduction to Pharmacokinetics and Pharmacodynamics. He was editor of the Journal of Pharmacokinetics and Pharmacodynamics (formerly Journal of Pharmacokinetics and Biopharmaceutics), 1973-2007, and established European and U.S.A. workshops for the teaching of basic, intermediate and advanced level pharmacokinetics. He consults widely for the pharmaceutical industry and serves on several company scientific advisory boards and the Governing Board of the European Union Network of Excellence in Biosimulation.

Hans Lennernäs, Ph.D.

Professor of Biopharmaceutics at Uppsala University and Adjunct Professor of Biopharmaceutics at the Royal Danish School of Pharmacy.

His research focuses on mechanisms and regulation of membrane transport and metabolism of drugs/metabolites in the gastrointestinal tract, hepatobiliary system and tumours through which he has developed two new clinical intestinal perfusion techniques.

Dr. Lennernäs is Chairman of the World Conference in Drug Absorption, Transport and Delivery (Barcelona, May 2005). Honours include the Glaxo Wellcome Achievement Award (1997), the Annual Award from the Industrial Pharmacy Section of the Fédération Internationale Pharmaceutique (FIP) (1998), and an Honourable Mention for the EURAND AWARD (2000).

Carl C. Peck, MD, Dr h.c. (Uppsala)

Chairman and Founder, NDA Partners LLC Adjunct Professor, UCSF, Center for Drug Development Science/UCSF UC-Washington, Washington, DC

Dr. Peck obtained a B.A. in mathematics and chemistry from the University of Kansas in 1963 and the M.D. in 1968. Following training in internal medicine, he undertook a research fellowship in clinical pharmacology at the University of California, San Francisco (1972-74). From 1974 to 1980, Dr. Peck was employed at the Letterman Army Institute of Research, San Francisco, CA, as Chief of the Army Blood Preservation Research Program. In 1980, Dr. Peck became Director of the Division of Clinical Pharmacology and, Professor, Departments of Medicine and Pharmacology, Uniformed Services University, Bethesda, Maryland.

Dr. Peck joined the FDA as Director, Center for Drug Evaluation and Research, in October 1987. He was promoted to Assistant Surgeon General in the Public Health Service in October 1990. Retiring from FDA in late 1993, Dr. Peck was appointed “Boerhaave” Professor of Clinical Drug Research at Leiden University in The Netherlands. In 1994 Professor Peck joined the faculty of the Georgetown University Medical Center, as the founding Director of the Center for Drug Development Science.

In 1999, Dr. Peck received the FDA Distinguished Alumnus Award. Sweden’s University of Uppsala conferred an honorary doctorate degree (Doctor Honoris Causa) to Dr. Peck in January 2002 in recognition of "outstanding contributions to the science of drug development". Dr. Peck founded NDA Partners LLC in 2003 and in 2004, CDDS moved to UCSF, located in the UC-Washington Center.

His research interests center on optimising informative value, efficiency, speed and economy of drug development and regulation using advanced concepts and techniques of clinical pharmacology, trial designs, and pharmaco-statistical modeling and simulation to generate causal evidence of effectiveness and safety. He is an author of more than 100 original research papers, chapters and books.

Brian Houston, Ph.D., D.Sc

Professor of Drug Metabolism & Pharmacokinetics and Director of the Centre for Applied Pharmacokinetic Research in the School of Pharmacy and Pharmaceutical Sciences at the University of Manchester in the UK. Chief Scientist

His research and teaching activities centre on quantitative drug metabolism and pharmacokinetics, in particular the prediction of drug metabolic clearance in humans, the molecular and kinetic basis of drug-drug interactions and genotypic/phenotypic sources of variability in metabolic clearance.

His research publications in the area of drug metabolite kinetics in vivo and in vitro exceed 200. He is a member of the editorial boards of several journals including Drug Metabolism & Disposition and Journal of Pharmacology and Experimental Therapeutics.